Da Cunha Eloïse, Plonka Alexandra, Arslan Seçkin, Mouton Aurélie, Meyer Tess, Robert Philippe, Meunier Fanny, Manera Valeria, Gros Auriane
Speech Therapy Department of Nice, Faculty of medicine, Université Côte d'Azur, 06000 Nice, France.
Laboratoire CoBTeK (Cognition Behaviour Technology), Université Côte d'Azur, 06000 Nice, France.
Life (Basel). 2022 Jun 22;12(7):933. doi: 10.3390/life12070933.
The logopenic variant of Primary Progressive Aphasia (lvPPA), a syndromic disorder centered on language impairment, often presents variable underlying neurodegenerative pathologies such as Alzheimer Disease (AD). Actual language assessment tests and lumbar puncture, focused on AD diagnosis, cannot precisely distinguish the symptoms, or predict their progression at onset time. We analyzed acoustic markers, aiming to discriminate lvPPA and AD as well as the influence of AD biomarkers on acoustic profiles at the beginning of the disease. We recruited people with AD (n = 8) and with lvPPA (n = 8), with cerebrospinal fluid biomarker profiles determined by lumbar puncture. The participants performed a sentence repetition task that allows assessing potential lvPPA phonological loop deficits. We found that temporal and prosodic markers significantly differentiate the lvPPA and AD group at an early stage of the disease. Biomarker and acoustic profile comparisons discriminated the two lvPPA subgroups according to their biomarkers. For lvPPA with AD biomarkers, acoustic profile equivalent to an atypical AD form with a specific alteration of the phonological loop is shown. However, lvPPA without AD biomarkers has an acoustic profile approximating the one for DLFT. Therefore, these results allow us to classify lvPPA differentially from AD based on acoustic markers from a sentence repetition task. Furthermore, our results suggest that acoustic analysis would constitute a clinically efficient alternative to refused lumbar punctures. It offers the possibility to facilitate early, specific, and accessible neurodegenerative diagnosis and may ease early care with speech therapy, preventing the progression of symptoms.
原发性进行性失语症(lvPPA)的语言迟缓变异型是一种以语言障碍为核心的综合征性疾病,常呈现多种潜在的神经退行性病变,如阿尔茨海默病(AD)。专注于AD诊断的实际语言评估测试和腰椎穿刺无法精确区分症状,也无法在发病时预测其进展。我们分析了声学标记,旨在区分lvPPA和AD,以及AD生物标志物在疾病初期对声学特征的影响。我们招募了AD患者(n = 8)和lvPPA患者(n = 8),通过腰椎穿刺确定其脑脊液生物标志物谱。参与者执行了一项句子重复任务,该任务可用于评估潜在的lvPPA语音回路缺陷。我们发现,时间和韵律标记在疾病早期能显著区分lvPPA组和AD组。生物标志物与声学特征的比较根据生物标志物区分了两个lvPPA亚组。对于具有AD生物标志物的lvPPA,显示出与具有语音回路特定改变的非典型AD形式等效的声学特征。然而,没有AD生物标志物的lvPPA具有接近DLFT的声学特征。因此,这些结果使我们能够根据句子重复任务中的声学标记对lvPPA和AD进行差异分类。此外,我们的结果表明,声学分析将成为拒绝腰椎穿刺时临床上有效的替代方法。它提供了促进早期、特异性和可及的神经退行性诊断的可能性,并可能通过言语治疗简化早期护理,防止症状进展。